JO
HRTX icon

John Overdeck’s Heron Therapeutics HRTX Stock Holding History

John Overdeck’s Portfolio HRTX Stock Details HRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$114K Sell
266,314
-51,086
-16% -$41K ﹤0.01% 4874
2026
Q1 		$254K Sell
317,400
-682,109
-68% -$790K ﹤0.01% 4169
2025
Q4 		$1.3M Buy
999,509
+307,230
+44% +$379K ﹤0.01% 2747
2025
Q3 		$872K Sell
692,279
-248,303
-26% -$394K ﹤0.01% 2671
2025
Q2 		$1.95M Sell
940,582
-112,399
-11% -$230K ﹤0.01% 1854
2025
Q1 		$2.32M Buy
1,052,981
+62,812
+6% +$122K 0.01% 1644
2024
Q4 		$1.51M Sell
990,169
-411,906
-29% -$668K ﹤0.01% 1906
2024
Q3 		$2.79M Buy
1,402,075
+295,639
+27% +$706K 0.01% 1462
2024
Q2 		$3.87M Buy
1,106,436
+1,025,872
+1,273% +$3.15M 0.01% 1128
2024
Q1 		$223K Buy
+80,564
New +$203K ﹤0.01% 2672
2023
Q3 		– Sell
-36,500
Closed -$42.3K – 3060
2023
Q2 		$42.3K Sell
36,500
-112,000
-75% -$200K ﹤0.01% 2844
2023
Q1 		$224K Sell
148,500
-124,581
-46% -$312K ﹤0.01% 2520
2022
Q4 		$683K Buy
273,081
+120,863
+79% +$389K ﹤0.01% 1885
2022
Q3 		$642K Buy
152,218
+45,163
+42% +$177K ﹤0.01% 1659
2022
Q2 		$299K Buy
+107,055
New +$430K ﹤0.01% 2027
2020
Q2 		– Sell
-116,226
Closed -$1.36M – 3189
2020
Q1 		$1.36M Sell
116,226
-17,757
-13% -$334K 0.01% 1202
2019
Q4 		$3.15M Buy
+133,983
New +$2.96M 0.01% 1248
2018
Q3 		– Sell
-8,780
Closed -$341K – 3360
2018
Q2 		$341K Buy
+8,780
New +$280K ﹤0.01% 2871

Other funds holding HRTX

RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
CC
Clearline Capital New York $1.68B AUM 53.07% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $164M AUM 542.31% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TC
Tejara Capital London, United Kingdom $243M AUM 9.84% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
JAM
JW Asset Management Miami Beach, Florida $320M AUM 140.1% 1-Year Est. Return

John Overdeck's HRTX Position: Q2 2026 in Review

John Overdeck reduced its Heron Therapeutics (HRTX) stake by 16% in Q2 2026, selling an estimated $41K and leaving 266,314 shares worth $114K. The position accounts for ﹤0.01% of the portfolio, ranked #4874.

John Overdeck first reported a position in HRTX in Q2 2018 and has held it in 18 quarters since. The position peaked at $3.87M in Q2 2024. 161 funds tracked by Wall St. Rank hold HRTX as of Q2 2026.

  • John Overdeck held 266,314 shares of Heron Therapeutics worth $114K as of Q2 2026.
  • John Overdeck sold 51,086 Heron Therapeutics shares in Q2 2026, an estimated $41K.
  • Heron Therapeutics made up ﹤0.01% of John Overdeck's portfolio in Q2 2026, its #4874 holding.
  • John Overdeck first reported a position in Heron Therapeutics in Q2 2018 and has held it in 18 quarters since.
  • John Overdeck's Heron Therapeutics position peaked at $3.87M in Q2 2024.
  • 161 funds tracked by Wall St. Rank held Heron Therapeutics as of Q2 2026.

Based on Two Sigma Investments's 13F filing for Q2 2026, filed 14 Aug 2026.